January 2019 is the final month to invest in BIOLIFE4D’s Regulation A+ offering to participate in the groundbreaking technology of 3D bioprinting human hearts viable for transplant. If you’re not familiar, in February 2018, BIOLIFE4D launched this offering to allow both accredited and non-accredited potential investors to consider helping us bring this historical, lifesaving technology to market. The offering began at $10 per share, but it did not stay that way for long.
After raising more than $1 million in only a few months, tremendous investor demand, significant media attention in outlets like USA Today and Fast Company, and rapid scientific progress, our share price increased by 20% to $12 per share.
And just days after announcing the update in the offering, we announced that we had successfully demonstrated our ability to 3D bioprint human cardiac tissue, which can be applied to patients with acute heart failure to restore their heartbeats, a major step toward our ultimate goal of 3D bioprinting human hearts.
In 2019, our immediate focus is on continuing that momentum to 3D bioprint a mini-heart. The mini-heart is clearly another major step toward the full-size heart but may also provide a solution to animal testing in the pharmaceutical industry and can save millions of animals’ lives. Each bit of scientific progress brings us closer to saving millions of human lives by making more hearts available for transplant.
Don’t miss out on the opportunity to be an investor in what is potentially one of humanity’s most important scientific and medical developments. But time is running out, so before our Regulation A+ offering closes at the end of January make sure you’ve done your part in supporting a project that may potentially save your own life or the lives of your family members. We all need hearts to survive, and this is everyone’s opportunity to do what we can to help this initiative succeed.